Integrated risk assessment of suicidal ideation and behavior in drug development

•We provide a brief outline of the clinical landscape and present labeling of compounds with suspected drug-induced suicidal intent and behavior (SIB).•The present regulatory recommendations for prospective assessment of SIB are highlighted.•We discuss the importance of target identification for SIB assessment in the preclinical setting.